Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Bases de dados
Idioma
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Zhonghua Yi Xue Za Zhi ; 83(11): 948-51, 2003 Jun 10.
Artigo em Zh | MEDLINE | ID: mdl-12899794

RESUMO

OBJECTIVE: To investigate the effects of treatment of malignant lymphoma (ML) by autologous hematopoietic stem cell transplantation (AHSCT) combined with high dose radiotherapy and chemotherapy. METHODS: From June 1991 to October 2002, 56 patients, aged 9 - 65 years, with ML, 44 non-Hodgkin's lymphoma (NHL) and 12 Hodgkin's disease (HD) were treated with AGSCT combined with high dose radiotherapy and chemotherapy. Among them, 12 received autologous bone marrow transplantation (ABMT) and 44 received autologous peripheral blood stem cell transplantation (APBSCT), In the latter the APBSCs were mobilized by carboplatin and etoposide (CE) or CHOP (CTX, ADM, VCR, PDN) plus granulocyte-colony stimulating factor (G-CSF) and/or granulocyte-macrophage colony stimulating factor (GM-CSF) 10 micro g/kg/d. Pretreatment included BEAM (BCNU, Vp-16, AraC, MEL) or MEL 140 mg/m(2) + Vp-16,200 mg/L total body irradiation (TBI) 8 Gy. The patients were flowed up for 40 - 4,310 days with a median of 1,820 days. RESULTS: Hematopoietic reconstruction was observed in all patients. The 1, 2, and 5-year disease-free survival rates were 87.5%, 60.7%, and 57.1% respectively, with the longest survival of 11 years. Fourteen patients developed relapse. No transplantation-related death was seen. CONCLUSION: Autologous hematopoietic stem cell transplantation combined with high dose radiotherapy and chemotherapy is effective on Ml. AHSCT shows a more rapid effect on hematopoietic reconstruction than ABMT.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Linfoma/terapia , Adolescente , Adulto , Idoso , Criança , Terapia Combinada , Feminino , Hematopoese , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Linfoma/mortalidade , Masculino , Pessoa de Meia-Idade , Recidiva , Transplante Autólogo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA